[{"orgOrder":0,"company":"Mutabilis","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"2G-Dabocins","moa":"Diazabicyclooctanes penicillin-binding proteins","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mutabilis","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Mutabilis \/ Novo Holdings","highestDevelopmentStatusID":"2","companyTruncated":"Mutabilis \/ Novo Holdings"},{"orgOrder":0,"company":"Vabiotech","sponsor":"Vingroup Innovation Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"VIETNAM","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vabiotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vabiotech \/ Vingroup Innovation Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Vabiotech \/ Vingroup Innovation Foundation"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrecise \/ Not Applicable"},{"orgOrder":0,"company":"NanoViricides","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"nCoV nanoviricide drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"NanoViricides","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"NanoViricides \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"NanoViricides \/ Not Applicable"},{"orgOrder":0,"company":"Kansas State University Research Foundation","sponsor":"Cocrystal Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"RdRp","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kansas State University Research Foundation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kansas State University Research Foundation \/ Cocrystal Pharma","highestDevelopmentStatusID":"2","companyTruncated":"Kansas State University Research Foundation \/ Cocrystal Pharma"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Mount Sinai Health System","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Human monoclonal antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nona Biosciences \/ Mount Sinai Health System","highestDevelopmentStatusID":"2","companyTruncated":"Nona Biosciences \/ Mount Sinai Health System"},{"orgOrder":0,"company":"Arcturus Therapeutics","sponsor":"Duke-NUS Medical School ","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Starr RNA","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arcturus Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Arcturus Therapeutics \/ Duke-NUS Medical School ","highestDevelopmentStatusID":"2","companyTruncated":"Arcturus Therapeutics \/ Duke-NUS Medical School "},{"orgOrder":0,"company":"GeoVax Labs","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GeoVax Labs","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GeoVax Labs \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"GeoVax Labs \/ Not Applicable"},{"orgOrder":0,"company":"Kamada","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-Corona (COVID-19) IgG product","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kamada","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kamada \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Kamada \/ Not Applicable"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Virus neutralizing antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Regeneron Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Vir Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 monoclonal antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vir Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vir Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Vir Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"HiFiBiO Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 neutralizing antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HiFiBiO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HiFiBiO Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"HiFiBiO Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Biocad","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SARS-COV-2 mRNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Biocad","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Biocad \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Biocad \/ Not Applicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrecise \/ Not Applicable"},{"orgOrder":0,"company":"Insilico Medicine","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"HONG KONG","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Insilico Medicine","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Insilico Medicine \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Insilico Medicine \/ Not Applicable"},{"orgOrder":0,"company":"Ethris","sponsor":"Neurimmune","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"NI007","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ethris","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Ethris \/ Neurimmune","highestDevelopmentStatusID":"2","companyTruncated":"Ethris \/ Neurimmune"},{"orgOrder":0,"company":"Adaptive Biotechnologies","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Human neutralizing antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Adaptive Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Adaptive Biotechnologies \/ Amgen","highestDevelopmentStatusID":"2","companyTruncated":"Adaptive Biotechnologies \/ Amgen"},{"orgOrder":0,"company":"Applied DNA Sciences Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"DNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied DNA Sciences Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Applied DNA Sciences Inc \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied DNA Sciences Inc \/ Not Applicable"},{"orgOrder":0,"company":"Scripps Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Scripps Research \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Scripps Research \/ Not Applicable"},{"orgOrder":0,"company":"Premas Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Premas Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Premas Biotech \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Premas Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Androgens","moa":"TMPRSS2 expression","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Not Applicable"},{"orgOrder":0,"company":"Applied Biology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Applied Biology","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Applied Biology \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Applied Biology \/ Not Applicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Coronavirus-neutralising antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AstraZeneca \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"AstraZeneca \/ Not Applicable"},{"orgOrder":0,"company":"Academia Sinica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Protease","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Academia Sinica","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Academia Sinica \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Academia Sinica \/ Not Applicable"},{"orgOrder":0,"company":"Shanghai Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shanghai Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Shanghai Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Shanghai Institute \/ Not Applicable"},{"orgOrder":0,"company":"Sosei Group Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Group Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sosei Group Corporation \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Group Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Celltrion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Monoclonal antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Celltrion","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Celltrion \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Celltrion \/ Not Applicable"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"State of North Dakota ","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Monocloncal antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ImmunoPrecise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ImmunoPrecise \/ State of North Dakota ","highestDevelopmentStatusID":"2","companyTruncated":"ImmunoPrecise \/ State of North Dakota "},{"orgOrder":0,"company":"Atreca","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"IgM antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atreca","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Atreca \/ BeiGene","highestDevelopmentStatusID":"2","companyTruncated":"Atreca \/ BeiGene"},{"orgOrder":0,"company":"University of Maryland","sponsor":"AIkido Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Antiviral drugs","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Maryland","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"University of Maryland \/ AIkido Pharma","highestDevelopmentStatusID":"2","companyTruncated":"University of Maryland \/ AIkido Pharma"},{"orgOrder":0,"company":"Q BioMed","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 drug","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Q BioMed","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Q BioMed \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Q BioMed \/ Not Applicable"},{"orgOrder":0,"company":"Nuritas","sponsor":"Advanced Computing in Europe","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Peptide","year":"2020","type":"Funding","leadProduct":"Peptides","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Nuritas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Nuritas \/ Advanced Computing in Europe","highestDevelopmentStatusID":"2","companyTruncated":"Nuritas \/ Advanced Computing in Europe"},{"orgOrder":0,"company":"Imophoron","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Imophoron","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Imophoron \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Imophoron \/ Not Applicable"},{"orgOrder":0,"company":"IDBiologics","sponsor":"Vanderbilt University Medical Center","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Monoclonal antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IDBiologics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IDBiologics \/ Vanderbilt University Medical Center","highestDevelopmentStatusID":"2","companyTruncated":"IDBiologics \/ Vanderbilt University Medical Center"},{"orgOrder":0,"company":"University of Waterloo","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"DNA based vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"University of Waterloo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"University of Waterloo \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"University of Waterloo \/ Not Applicable"},{"orgOrder":0,"company":"MIGAL Research Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ISRAEL","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"COVID-19 vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MIGAL Research Institute","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"MIGAL Research Institute \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"MIGAL Research Institute \/ Not Applicable"},{"orgOrder":0,"company":"Atomwise","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"IL-6 Signalling Pathway","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Undisclosed","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Undisclosed"},{"orgOrder":0,"company":"Shionogi","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Prophylactic recombinant protein vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ Not Applicable"},{"orgOrder":0,"company":"Abcore","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Single domain antibodies","moa":"ACE2","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Abcore","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Abcore \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Abcore \/ Not Applicable"},{"orgOrder":0,"company":"Secarna Pharma","sponsor":"Sun Yat-sen University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Antisense oligonucleotides","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Secarna Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Secarna Pharma \/ Sun Yat-sen University","highestDevelopmentStatusID":"2","companyTruncated":"Secarna Pharma \/ Sun Yat-sen University"},{"orgOrder":0,"company":"Codiak BioSciences","sponsor":"Ragon Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"exoVACC","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Codiak BioSciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Codiak BioSciences \/ Ragon Institute","highestDevelopmentStatusID":"2","companyTruncated":"Codiak BioSciences \/ Ragon Institute"},{"orgOrder":0,"company":"Memo Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"SARS-CoV-2-neutralizing antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Memo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Memo Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Memo Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Proteona","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Neutralizing antibody therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Proteona","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Proteona"},{"orgOrder":0,"company":"HitGen","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Evotec SE","highestDevelopmentStatusID":"2","companyTruncated":"HitGen \/ Evotec SE"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Immunomic Therapeutics","sponsor":"Replicate Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Licensing Agreement","leadProduct":"RBI-5000","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Immunomic Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Immunomic Therapeutics \/ Replicate Bioscience","highestDevelopmentStatusID":"2","companyTruncated":"Immunomic Therapeutics \/ Replicate Bioscience"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Vaccine","year":"2020","type":"Expanded Collaboration","leadProduct":"mRNA vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sanofi \/ Sanofi","highestDevelopmentStatusID":"2","companyTruncated":"Sanofi \/ Sanofi"},{"orgOrder":0,"company":"SciLifeLab","sponsor":"Medivir","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"SARS CoV-2 protease","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SciLifeLab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SciLifeLab \/ Medivir","highestDevelopmentStatusID":"2","companyTruncated":"SciLifeLab \/ Medivir"},{"orgOrder":0,"company":"Hackensack Meridian CDI","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hackensack Meridian CDI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Hackensack Meridian CDI \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Hackensack Meridian CDI \/ Merck"},{"orgOrder":0,"company":"ZYUS Life Sciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Plant-based COVID-19 antigen","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ZYUS Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ZYUS Life Sciences \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"ZYUS Life Sciences \/ Not Applicable"},{"orgOrder":0,"company":"Dewpoint Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dewpoint Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dewpoint Therapeutics \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"Dewpoint Therapeutics \/ Merck"},{"orgOrder":0,"company":"VenatoRx Pharmaceuticals","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Non-beta-lactam antibiotic","moa":"PBP","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VenatoRx Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"VenatoRx Pharmaceuticals \/ NIAID","highestDevelopmentStatusID":"2","companyTruncated":"VenatoRx Pharmaceuticals \/ NIAID"},{"orgOrder":0,"company":"IRBM","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IRBM","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IRBM \/ Merck","highestDevelopmentStatusID":"2","companyTruncated":"IRBM \/ Merck"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-SARS-CoV-2 S1 Antibody","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Twist Bioscience \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Not Applicable"},{"orgOrder":0,"company":"IsoTherapeutics Group","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MNPR-101","moa":"uPAR","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IsoTherapeutics Group","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"2","companyTruncated":"IsoTherapeutics Group \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"LITHUANIA","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"MTX-COVAB","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Northway Biotechpharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Northway Biotechpharma \/ Memo Therapeutics AG","highestDevelopmentStatusID":"2","companyTruncated":"Northway Biotechpharma \/ Memo Therapeutics AG"},{"orgOrder":0,"company":"BenevolentAI","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BenevolentAI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"BenevolentAI \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"BenevolentAI \/ Not Applicable"},{"orgOrder":0,"company":"Kao Corporation","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"Cry5B protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kao Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kao Corporation \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Kao Corporation \/ GHIT Fund"},{"orgOrder":0,"company":"MILLENNIUM PHARMS","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"MILLENNIUM PHARMS","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"MILLENNIUM PHARMS \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"MILLENNIUM PHARMS \/ GHIT Fund"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Daiichi Sankyo \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Daiichi Sankyo \/ GHIT Fund"},{"orgOrder":0,"company":"Atomwise","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Atomwise \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Atomwise \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"The Pirbright Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"PRRSV vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Enesi Pharma Limited","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Enesi Pharma Limited \/ The Pirbright Institute","highestDevelopmentStatusID":"2","companyTruncated":"Enesi Pharma Limited \/ The Pirbright Institute"},{"orgOrder":0,"company":"Oblique Therapeutics","sponsor":"Vinnova","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWEDEN","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"\u03b1SARS-CoV-2 antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Oblique Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Oblique Therapeutics \/ Vinnova","highestDevelopmentStatusID":"2","companyTruncated":"Oblique Therapeutics \/ Vinnova"},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Funding","leadProduct":"Anti-SARS-CoV-2 antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"IAVI","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Agreement","leadProduct":"SARS-CoV-2 neutralising monoclonal antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"IAVI","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"IAVI \/ Merck KGaA","highestDevelopmentStatusID":"2","companyTruncated":"IAVI \/ Merck KGaA"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"T Cell","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"TScan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Epsilon Molecular Engineering","sponsor":"Mitsubishi UFJ Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Series A Financing","leadProduct":"VHH antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Epsilon Molecular Engineering","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Epsilon Molecular Engineering \/ Mitsubishi UFJ Capital","highestDevelopmentStatusID":"2","companyTruncated":"Epsilon Molecular Engineering \/ Mitsubishi UFJ Capital"},{"orgOrder":0,"company":"Repertoire Immune Medicines","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Repertoire Immune Medicines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Repertoire Immune Medicines \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Repertoire Immune Medicines \/ Not Applicable"},{"orgOrder":0,"company":"Cipla","sponsor":"SIGA Technologies","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Cipla","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Cipla \/ SIGA Technologies","highestDevelopmentStatusID":"2","companyTruncated":"Cipla \/ SIGA Technologies"},{"orgOrder":0,"company":"Rokote Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FINLAND","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Rokote Lab","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal spray","sponsorNew":"Rokote Lab \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Rokote Lab \/ Not Applicable"},{"orgOrder":0,"company":"Iontas","sponsor":"FairJourney Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Neutralizing antibodies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Iontas","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Iontas \/ FairJourney Biologics","highestDevelopmentStatusID":"2","companyTruncated":"Iontas \/ FairJourney Biologics"},{"orgOrder":0,"company":"Codebase","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Hydroxychloroquine Sulphate","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Codebase","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Codebase \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Codebase \/ Not Applicable"},{"orgOrder":0,"company":"TB Alliance","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TB Alliance","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TB Alliance \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"TB Alliance \/ Astellas"},{"orgOrder":0,"company":"Gifu University","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Next-generation phage therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Gifu University","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Gifu University \/ Astellas","highestDevelopmentStatusID":"2","companyTruncated":"Gifu University \/ Astellas"},{"orgOrder":0,"company":"Evrys Bio","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"SIRT-2 protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evrys Bio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Evrys Bio \/ US Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evrys Bio \/ US Department of Defense"},{"orgOrder":0,"company":"Indian Institute of Science","sponsor":"Ignite Life Science Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Vaccine","year":"2021","type":"Funding","leadProduct":"mRNA Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Indian Institute of Science","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Indian Institute of Science \/ Ignite Life Science Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Indian Institute of Science \/ Ignite Life Science Foundation"},{"orgOrder":0,"company":"TScan Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"TCR-T cell therapies","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TScan Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TScan Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"TScan Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"2F8","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intranasal","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Bio-Thera Solutions \/ Not Applicable"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"SARS-CoV-2 Pseudotyped Reporter Virus Particles","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Integral Molecular \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Integral Molecular \/ Not Applicable"},{"orgOrder":0,"company":"Exscientia","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Exscientia \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"EpiVax","sponsor":"Leidos","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Malaria Vaccine","moa":"CSP","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"EpiVax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"EpiVax \/ Leidos","highestDevelopmentStatusID":"2","companyTruncated":"EpiVax \/ Leidos"},{"orgOrder":0,"company":"Hudson Institute of Medical Research","sponsor":"Noxopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"mRNA Vaccine","moa":"TLR7","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Hudson Institute of Medical Research","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Hudson Institute of Medical Research \/ Noxopharm","highestDevelopmentStatusID":"2","companyTruncated":"Hudson Institute of Medical Research \/ Noxopharm"},{"orgOrder":0,"company":"Arbutus Biopharma","sponsor":"Proteros","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Arbutus Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Arbutus Biopharma \/ Proteros","highestDevelopmentStatusID":"2","companyTruncated":"Arbutus Biopharma \/ Proteros"},{"orgOrder":0,"company":"Affinivax","sponsor":"CEPI","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Partnership","leadProduct":"Covid-19 Vaccine","moa":"SARS-CoV-2 spike protein","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Affinivax","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Affinivax \/ CEPI","highestDevelopmentStatusID":"2","companyTruncated":"Affinivax \/ CEPI"},{"orgOrder":0,"company":"Sosei Heptares","sponsor":"Wellcome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Small molecule","year":"2021","type":"Funding","leadProduct":"SH-879","moa":"Mpro","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sosei Heptares","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Sosei Heptares \/ Wellcome","highestDevelopmentStatusID":"2","companyTruncated":"Sosei Heptares \/ Wellcome"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Sosei Group Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Twist Bioscience \/ Sosei Group Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Twist Bioscience \/ Sosei Group Corporation"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Collaboration","leadProduct":"Protein-based Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Dyadic International, Inc \/ Janssen","highestDevelopmentStatusID":"2","companyTruncated":"Dyadic International, Inc \/ Janssen"},{"orgOrder":0,"company":"Dante Labs","sponsor":"The Renato Dulbecco Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Partnership","leadProduct":"Pronectines Nanoantibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dante Labs","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Dante Labs \/ The Renato Dulbecco Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Dante Labs \/ The Renato Dulbecco Foundation"},{"orgOrder":0,"company":"Emergex Vaccines Holding","sponsor":"Department of Health and Social Care","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Synthetic T-cell Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Emergex Vaccines Holding","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Microneedle Patch","sponsorNew":"Emergex Vaccines Holding \/ Department of Health and Social Care","highestDevelopmentStatusID":"2","companyTruncated":"Emergex Vaccines Holding \/ Department of Health and Social Care"},{"orgOrder":0,"company":"Spexis","sponsor":"CARB-X","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Peptide","year":"2022","type":"Funding","leadProduct":"POL7306","moa":"LPS transport pathway","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Spexis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Spexis \/ CARB-X","highestDevelopmentStatusID":"2","companyTruncated":"Spexis \/ CARB-X"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbbVie Inc \/ Scripps Research","highestDevelopmentStatusID":"2","companyTruncated":"AbbVie Inc \/ Scripps Research"},{"orgOrder":0,"company":"Altesa Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Altesa Biosciences","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Altesa Biosciences \/ NIH","highestDevelopmentStatusID":"2","companyTruncated":"Altesa Biosciences \/ NIH"},{"orgOrder":0,"company":"Metropolitan AntiViral Drug Accelerator","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Funding","leadProduct":"Antiviral Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Metropolitan AntiViral Drug Accelerator","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Metropolitan AntiViral Drug Accelerator \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Metropolitan AntiViral Drug Accelerator \/ National Institutes of Health"},{"orgOrder":0,"company":"Phase Genomics","sponsor":"Bill and Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Funding","leadProduct":"Phage Therapeutic","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Phase Genomics","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Phase Genomics \/ Bill and Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Phase Genomics \/ Bill and Melinda Gates Foundation"},{"orgOrder":0,"company":"Touchlight","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Touchlight \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Touchlight \/ Not Applicable"},{"orgOrder":0,"company":"GreenLight Biosciences","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"mRNA-Based COVID-19 Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"GreenLight Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"GreenLight Biosciences \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"GreenLight Biosciences \/ National Institutes of Health"},{"orgOrder":0,"company":"Vernalis","sponsor":"Unison Medicines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vernalis \/ Unison Medicines","highestDevelopmentStatusID":"2","companyTruncated":"Vernalis \/ Unison Medicines"},{"orgOrder":0,"company":"Just \u2013 Evotec Biologics","sponsor":"Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Agreement","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Just \u2013 Evotec Biologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Just \u2013 Evotec Biologics \/ Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Just \u2013 Evotec Biologics \/ Department of Defense"},{"orgOrder":0,"company":"Genomic Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"Dellera","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Genomic Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Genomic Biopharma \/ Not Applicable","highestDevelopmentStatusID":"2","companyTruncated":"Genomic Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Sirona Biochem Corp","sponsor":"International Centre for Genetic Engineering and Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Antiviral Therapeutics","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Sirona Biochem Corp","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology","highestDevelopmentStatusID":"2","companyTruncated":"Sirona Biochem Corp \/ International Centre for Genetic Engineering and Biotechnology"},{"orgOrder":0,"company":"Iktos","sponsor":"Medicines for Malaria Venture","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Iktos","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Iktos \/ Medicines for Malaria Venture","highestDevelopmentStatusID":"2","companyTruncated":"Iktos \/ Medicines for Malaria Venture"},{"orgOrder":0,"company":"Clear Creek Bio","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Clear Creek Bio","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Clear Creek Bio \/ Pfizer","highestDevelopmentStatusID":"2","companyTruncated":"Clear Creek Bio \/ Pfizer"},{"orgOrder":0,"company":"CytomX Therapeutics","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"CytomX Therapeutics","amount2":1.24,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":1.24,"dosageForm":"","sponsorNew":"CytomX Therapeutics \/ Moderna","highestDevelopmentStatusID":"2","companyTruncated":"CytomX Therapeutics \/ Moderna"},{"orgOrder":0,"company":"Imunon","sponsor":"The Wistar Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Imunon","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Imunon \/ The Wistar Institute","highestDevelopmentStatusID":"2","companyTruncated":"Imunon \/ The Wistar Institute"},{"orgOrder":0,"company":"Medical College of Wisconsin","sponsor":"Infant Bacterial Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Medical College of Wisconsin","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Medical College of Wisconsin \/ Infant Bacterial Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Medical College of Wisconsin \/ Infant Bacterial Therapeutics"},{"orgOrder":0,"company":"Blue Water Vaccines","sponsor":"AbVacc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Monkeypox Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Blue Water Vaccines","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Blue Water Vaccines \/ AbVacc","highestDevelopmentStatusID":"2","companyTruncated":"Blue Water Vaccines \/ AbVacc"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Takeda Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Takeda Pharmaceutical \/ GHIT Fund"},{"orgOrder":0,"company":"Shionogi","sponsor":"Nagasaki University","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ Nagasaki University","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ Nagasaki University"},{"orgOrder":0,"company":"Shionogi","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Shionogi \/ GHIT Fund","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ GHIT Fund"},{"orgOrder":0,"company":"SpyBiotech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SpyBiotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SpyBiotech \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"SpyBiotech \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"AbCellera","sponsor":"RQ Bio","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AbCellera \/ RQ Bio","highestDevelopmentStatusID":"2","companyTruncated":"AbCellera \/ RQ Bio"},{"orgOrder":0,"company":"Evotec","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"Evotec \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"bitBiome","sponsor":"Kaken Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"bitBiome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"bitBiome \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"bitBiome \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"InSilicoTrials","sponsor":"Achilles Vaccines","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"InSilicoTrials","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"InSilicoTrials \/ AchilleS Vaccines","highestDevelopmentStatusID":"2","companyTruncated":"InSilicoTrials \/ AchilleS Vaccines"},{"orgOrder":0,"company":"Evotec","sponsor":"Open Philanthropy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Evotec \/ Open Philanthropy","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Open Philanthropy"},{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Quadrivalent Cell Culture-based Influenza Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"SK Bioscience \/ Doherty Institute","highestDevelopmentStatusID":"2","companyTruncated":"SK Bioscience \/ Doherty Institute"},{"orgOrder":0,"company":"Evotec","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"GERMANY","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Monoclonal Antibody","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Evotec","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Evotec \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ U.S. Department of Defense"},{"orgOrder":0,"company":"VitriVax","sponsor":"Defense Threat Reduction Agency","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"Thermostable Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"VitriVax","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"VitriVax \/ Defense Threat Reduction Agency","highestDevelopmentStatusID":"2","companyTruncated":"VitriVax \/ Defense Threat Reduction Agency"},{"orgOrder":0,"company":"TC BioPharm","sponsor":"Queen Mary University of London","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"TC BioPharm","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"TC BioPharm \/ Queen Mary University of London","highestDevelopmentStatusID":"2","companyTruncated":"TC BioPharm \/ Queen Mary University of London"},{"orgOrder":0,"company":"AN2 Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"AN2 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"AN2 Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Omniose","sponsor":"National Institute of Allergy and Infectious Diseases","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Funding","leadProduct":"GBS Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Omniose","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Omniose \/ National Institute of Allergy and Infectious Diseases","highestDevelopmentStatusID":"2","companyTruncated":"Omniose \/ National Institute of Allergy and Infectious Diseases"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"2","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"Vetophage","sponsor":"PHAXIAM Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Vetophage","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Vetophage \/ PHAXIAM Therapeutics","highestDevelopmentStatusID":"2","companyTruncated":"Vetophage \/ PHAXIAM Therapeutics"},{"orgOrder":0,"company":"Inimmune","sponsor":"Boston Children's Hospital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Inimmune","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Inimmune \/ Boston Children's Hospital","highestDevelopmentStatusID":"2","companyTruncated":"Inimmune \/ Boston Children's Hospital"},{"orgOrder":0,"company":"Exscientia","sponsor":"Open Philanthropy","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Exscientia","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Exscientia \/ Open Philanthropy","highestDevelopmentStatusID":"2","companyTruncated":"Exscientia \/ Open Philanthropy"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"2","companyTruncated":"Ginkgo Bioworks \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"H3D Foundation","sponsor":"LifeArc","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH AFRICA","productType":"Small molecule","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"H3D Foundation","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"","sponsorNew":"H3D Foundation \/ LifeArc","highestDevelopmentStatusID":"2","companyTruncated":"H3D Foundation \/ LifeArc"},{"orgOrder":0,"company":"Ennaid Therapeutics","sponsor":"Strides Pharma Science","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Ennaid Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ennaid Therapeutics \/ Strides Pharma Science","highestDevelopmentStatusID":"2","companyTruncated":"Ennaid Therapeutics \/ Strides Pharma Science"},{"orgOrder":0,"company":"Dyadic International, Inc","sponsor":"Israel Institute for Biological Research","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Dyadic International, Inc","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Dyadic International, Inc \/ Israel Institute for Biological Research","highestDevelopmentStatusID":"2","companyTruncated":"Dyadic International, Inc \/ Israel Institute for Biological Research"},{"orgOrder":0,"company":"RevolKa","sponsor":"La Jolla Institute for Immunology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Vaccine","year":"2024","type":"Collaboration","leadProduct":"RK009","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"RevolKa","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"RevolKa \/ La Jolla Institute for Immunology","highestDevelopmentStatusID":"2","companyTruncated":"RevolKa \/ La Jolla Institute for Immunology"},{"orgOrder":0,"company":"Shionogi","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Shionogi","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Shionogi \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Shionogi \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"Eisai","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Eisai","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Eisai \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Eisai \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"Mitsubishi Tanabe Pharma","sponsor":"The Global Health Innovative Technology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Mitsubishi Tanabe Pharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Mitsubishi Tanabe Pharma \/ The Global Health Innovative Technology","highestDevelopmentStatusID":"2","companyTruncated":"Mitsubishi Tanabe Pharma \/ The Global Health Innovative Technology"},{"orgOrder":0,"company":"BioVersys AG","sponsor":"CF AMR Syndicate","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"BV500","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"BioVersys AG","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"BioVersys AG \/ CF AMR Syndicate","highestDevelopmentStatusID":"2","companyTruncated":"BioVersys AG \/ CF AMR Syndicate"},{"orgOrder":0,"company":"Versatope Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Versatope Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Versatope Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"2","companyTruncated":"Versatope Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"CORTx","sponsor":"MRFF","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Large molecule","year":"2024","type":"Funding","leadProduct":"mRNA-based Therapy","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"CORTx","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"CORTx \/ MRFF","highestDevelopmentStatusID":"2","companyTruncated":"CORTx \/ MRFF"},{"orgOrder":0,"company":"Aurigene Pharmaceutical Services","sponsor":"Kainomyx","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Aurigene Pharmaceutical Services","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Aurigene Pharmaceutical Services \/ Kainomyx","highestDevelopmentStatusID":"2","companyTruncated":"Aurigene Pharmaceutical Services \/ Kainomyx"},{"orgOrder":0,"company":"ATCC (American Type Culture Collection)","sponsor":"NIAID","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Funding","leadProduct":"Babesia Vaccine","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"ATCC (American Type Culture Collection)","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"ATCC (American Type Culture Collection) \/ NIAID","highestDevelopmentStatusID":"2","companyTruncated":"ATCC (American Type Culture Collection) \/ NIAID"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ U.S. Department of Defense","highestDevelopmentStatusID":"2","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ U.S. Department of Defense"}]
Find Novel Drugs for Infections and Infectious Diseases under Discovery
Details :
Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry.
Details :
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation to deliver next generation oral antiviral treatments.
Details :
The two companies will build upon their existing collaboration to pursue novel mRNA vaccines aimed at broadly addressing current and future infectious diseases.
Details :
The proceeds will be used to advance babesiosis and tickborne disease research by addressing an underappreciated and understudied area of babesia biology and pathogenesis.
Details :
The agreement aims to develop small molecule broad-spectrum antiviral agents for the treatment of infections to improve the medical readiness of military personnel in biological threat environments.
Details :
The Versatope will use the grant to develop a bi-specific malaria vaccine using a target that blocks both the initial malaria infection and transmission.
Details :
The funding will aim to advance the clinical development of CORTx RNA therapeutic candidates for the treatment of infectious diseases such as COVID-19.
Details :
The proceeds will support the development of novel small molecules targeting difficult to treat non-tubercular mycobacteria lung disease (NTM-LD) in people with cystic fibrosis (CF).
Details :
The net proceeds will be used for the lead optimization and candidate selection of a novel LA-injectable which targets malarial electron transport chain for malaria chemoprevention and prophylaxis.
Details :
The net proceeds will be used to evaluate the safety and efficacy profiles of next-generation cPheRS-inhibitor antimalarials, with potentially lower cost of treatment and improved safety profiles.
Reset All
Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.
